1950
"Although no clear-cut evidence of immunodeficiency could be demonstrated in our patient, this could not be ruled out completely." 
-2004

Approved Antiretroviral Agents in 2004
Nucleoside RTIs • Zidovudine (ZDV)
Protease Inhibitors ART 2009 Easier, less toxic, and more potent therapy High (≥ 90% adherence; 49% of visits)
68% efficacy
Intermediate (50-90% adherence; 33% of visits)
34% efficacy
Low (< 50% adherence;18% of visits)
16% efficacy
• 9% of seroconverters had detectable drug at first HIV+ visit -vs 51% of nonseroconverters Grant et al, NEJM 2010 HPTN 052 
